Comprehensive Study Guide on Reproduction, HPG Axis, and Sexual Differentiation, and Folliculogenesis

Sexual Determination and Differentiation

  • Sexual Determination: Refers to the genetically controlled processes that are dependent on the 'switch' located on the Y chromosome. It is the chromosomal determination of an individual as male or female.
  • Sexual Differentiation: The process by which the internal and external genitalia develop as specifically male or female.
  • Bipotential Gonads: Post-fertilization, the gonads are classified as bipotential, meaning they have the potential to develop into either testes or ovaries.
  • Sex Classifications:     * Genotypic Sex: The specific genotype of the sex chromosomes (XXXX in females and XYXY in males).     * Gonadal Sex: Refers to whether an individual possesses testes or ovaries; while usually aligned with genotypic sex, certain disorders can cause discrepancies.     * Phenotypic Sex: The physical appearance of an individual resulting from gene expression; typically matches genotypic and gonadal sex.     * Legal Sex: The sex assigned on a birth certificate, which carries social and legal implications (e.g., sports, royal succession).     * Gender Identity: A patient’s internal sense of self and how they identify, which may not correspond to biological sex.
  • The SRY Gene: The Sex-determining Region Y (SRYSRY) gene is the primary factor in forming testes. It switches on briefly during embryo development (before the 7th7^{th} week) to direct the gonad to become a testis. In its absence, an ovary forms.
  • Bipotential Precursors: Common somatic mesenchymal tissue precursors (genital ridge primordia) develop between 3.53.5 and 4.54.5 weeks of gestation on the posterior wall of the lower thoracic lumbar region.

The Three Waves of Genital Ridge Invasion

  • Wave 1: Primordial Germ Cells (PGCs):     * Identifiable in the yolk sac at 33 weeks post-conception.     * They multiply by mitosis and migrate via chemotaxis to the genital ridge by 66 weeks.     * These cells become bipotential and diploid; they eventually differentiate into sperm cells (MM) or oocytes (FF).
  • Wave 2: Primitive Sex Cords:     * Originating from the germinal epithelium overlying the genital ridge mesenchyme, these cells migrate inwards as columns.     * In Males: Become Sertoli cells, which secrete SRYSRY and Anti-Mullerian Hormone (AMHAMH). They penetrate the medullary mesenchyme to form testis cords (precursor to seminiferous tubules).     * In Females: Become Granulosa cells. Because there is no SRYSRY, sex cords are ill-defined and condense in the cortex as small clusters around PGCs (precursors of ovarian follicles).
  • Wave 3: Mesonephric Cells:     * Originate from the mesonephric primordium lateral to the genital ridges.     * In Males: Under the influence of pre-Sertoli cells (expressing SRYSRY), they form vascular tissue, Leydig cells (which synthesize testosterone but do not express SRYSRY), and the basement membrane (contributing to seminiferous tubules and rete-testis).     * In Females: Without SRYSRY influence, they differentiate into vascular tissue and Theca cells.

Development of Internal and External Genitalia

  • The Duct Systems:     * Mullerian Ducts (Paramesonephric): Found in both initially; in females, they develop into the uterine tubes, uterus, and the upper 1/3rd1/3^{rd} of the vagina. In males, they are inhibited by AMHAMH.     * Wolffian Ducts (Mesonephric): In males, stimulated by testosterone to develop into the epididymis, vas deferens, and parts of the prostate. In females, the lack of testosterone causes them to regress.
  • External Genital Differentiation:     * The Role of 5-α-reductase: This enzyme in the genital skin converts testosterone into the more potent androgen Dihydrotestosterone (DHTDHT).     * Action of DHT: DHTDHT is 10×10 × more potent than testosterone. It binds to the testosterone receptor to cause the clitoral area to enlarge into a penis, the labia to fuse and become ruggated to form the scrotum, and the formation of the prostate.     * Female External Genitalia: Females possess 5-α-reductase5\text{-α-reductase} but lack testosterone (no Leydig cells), leading to the development of the vagina, labia, and clitoris. The line down the penis where the urethral fold joins is analogous to the clitoris in females.

Disorders of Sexual Development (DSD)

  • Turner Syndrome (45,XO45,XO):     * Results in streak ovaries (ovarian dysgenesis), illustrating that two XX chromosomes are required for normal ovarian development.     * Contains a pseudoautosomal region on the second XX necessary for growth.     * Phenotype: Female external genitalia, small uterus/tubes; may require hormonal support for bone and uterine health (estrogen and progesterone).
  • Androgen Insensitivity Syndrome (AIS):     * XYXY individual with SRYSRY gene; testes form and Sertoli cells produce AMHAMH.     * Mullerian ducts regress (no uterus), but a mutation in the androgen receptor means testosterone and DHTDHT have no effect.     * Wolffian ducts regress; external genitalia appear feminine. Often presents as primary amenorrhea with male levels of androgens.
  • 5-α-Reductase Deficiency:     * XYXY individual with testes and AMHAMH production (Mullerian regression).     * Internal male genitalia develop (Wolffian structures), but testosterone cannot convert to DHTDHT.     * Result: Feminine or atypical external genitalia at birth; virilization (development of male genitalia) occurs at puberty due to high testosterone levels during adrenarche/gonadarche.
  • Congenital Adrenal Hyperplasia (CAH):     * XXXX individual; the most common form is 21-hydroxylase21\text{-hydroxylase} deficiency.     * Pathway block prevents progesterone conversion to cortisol and aldosterone. High ACTHACTH leads to massive androgen production.     * Result: External genitalia are masculinized; however, there is no SRYSRY or AMHAMH, so internal genitalia (uterus, tubes) remain feminine. Can cause lethal salt-wasting due to lack of aldosterone.
  • Klinefelter’s Syndrome (XXYXXY): A form of hypergonadotrophic hypogonadism resulting in delayed puberty and gonadal dysgenesis.

The HPG Axis: Structure and Function

  • The Axis Hierarchy:     1. Hypothalamus: Arcuate and preoptic nuclei release GnRH.     2. Anterior Pituitary: Gonadotrophs respond to GnRH by releasing FSHFSH and LHLH.     3. Gonads: Stimulated by FSHFSH/LHLH to produce gametes and sex steroids (estrogen, progesterone, testosterone).
  • Kisspeptin:     * Essential for initiating puberty.     * Expressed in the arcuate and anteroventral periventricular nucleus (AVPVAVPV).     * Kisspeptin neurons project to GnRH neurons, which possess kisspeptin receptors (KISS1RKISS1R), triggering GnRH synthesis and release.     * Reduced expression leads to hypogonadotrophic hypogonadism.
  • Kisspeptin Structure: Translated as a inactive 145aa145\text{aa} prepropeptide; cleaved into four active peptides. All contain a C-terminal Arg-Phe-NH2NH_2 motif (RF-amide family) to activate the KISS1KISS1 receptor.
  • Anterior Pituitary Hormones: FSHFSH, LHLH, TSHTSH, ACTHACTH, GHGH, and PRLPRL.
  • Posterior Pituitary Hormones: Oxytocin and ADHADH (Vasopressin).
  • Pituitary Blood Supply:     * Superior Hypophyseal Artery: Supplies the upper infundibulum (capillary network).     * Portal Vessels: Deliver regulatory hormones (like GnRH) from the hypothalamus to the anterior lobe.     * Inferior Hypophyseal Artery: Supplies the posterior lobe.     * Hypophyseal Veins: Carry hormones to the systemic circulation.

GnRH Secretion and Regulation

  • GnRH Molecular Structure: Initially a larger peptide with a signal peptide. The active decapeptide (10aa10\text{aa}) is co-secreted with GnRH-associated peptide (GAPGAP, 56aa56\text{aa}). Endopeptidases cleave it at processing site P.
  • Pulsatile Release: GnRH is released every 3012030-120 minutes.     * Slow Pulse Frequency: Favors FSHFSH release.     * Rapid Pulse Frequency: Favors LHLH release.     * Continuous Release: Causes downregulation and decoupling of the GPCR from its second messenger system, switching off the HPG axis.
  • GnRH Analogs:     * Agonists: Used in IVF to induce ovulation or as puberty blockers (desensitize the pituitary).     * Antagonists: Directly block GnRH action on the pituitary.
  • Gonadotrophin Structure: Heterodimeric peptides with an alpha and beta chain. The alpha chain is identical for FSHFSH, LHLH, TSHTSH, and hCGhCG. The beta chain is unique (detected in pregnancy tests for hCGhCG).

Puberty: Adrenarche, Pubarche, and Gonadarche

  • Definition: The transition from a non-reproductive to a reproductive state involving physiological and psychological changes.
  • Precocious Puberty Thresholds: Under age 88 in girls; under age 99 in boys.
  • Adrenarche (1st1^{st} event):     * Maturation of the zona reticularis in the adrenal cortex.     * Leads to secretion of androgens (DHEADHEA and DHEASDHEAS).     * Levels increase from age 1010, peak in mid-20s20s, and decline thereafter.
  • Pubarche: Appearance of pubic and axillary hair due to adrenal androgens.     * Pilosebaceous Units (PSUs):         * Vellous PSUs: Fine body hair (everywhere except palms/soles).         * Terminal PSUs: Develop into moustache and beard hair.         * Apocrine PSUs: Located in armpits/groin; form pubic/axillary hair and scent glands.         * Sebaceous PSUs: Large glands secreting sebum under androgen influence; blockage leads to acne.
  • Gonadarche: HPG axis-driven. Pituitary FSHFSH and LHLH activate gonadal function.     * Male: LHLH stimulates steroid synthesis; FSHFSH stimulates testis growth.     * Female: LHLH stimulates steroid synthesis; FSHFSH stimulates folliculogenesis.
  • HPG Activation Timeline:     * Activated at the 16th16^{th} gestational week.     * Continues until 121-2 years postnatally.     * Restrained for approximately 1010 years before reactivation at gonadarche.
  • LH Patterns:     * Early puberty: Nocturnal rise in LH secretion.     * As puberty progresses: Consistent pulsatile release.     * Adult: Pulsatile release occurs throughout the day.

Growth, Nutrition, and the Tanner Scale

  • Linear Growth: Estrogen has a biphasic effect on epiphyses (rounded ends of long bones).     * Low Estrogen: Promotes linear bone growth (growth spurt).     * High Estrogen: Causes fusion of epiphyses to the shaft, stopping growth.     * Timing: Growth spurt begins approximately 22 years earlier in girls.
  • Theories on Puberty Onset:     1. Genetic/Maturation: Maturation of 100030001000-3000 GnRH neurons.     2. Body Fat/Nutrition: Necessity of 171817-18 ᐱ body fat to initiate and 2222 ᐱ to maintain the cycle; linked to leptin levels.     3. Kisspeptin: Mutations in kisspeptin signalling can advance or delay puberty.
  • Consonance: The smooth, ordered progression of pubertal changes. While timing varies, the sequence remains the same.
  • Tanner Scale (Stages 1-5):     * Stage 1: Pre-pubertal.     * Stage 2 (Ages 8-11.5): Pubarche (both); testicular enlargement (M); thelarche/breast buds (F).     * Stage 3 (Ages 11.5-13): Coarsening of pubic hair; penis length increase; breast mound forms.     * Stage 4 (Ages 13-15): Penis width/glans increase; raised areola (mound on mound).     * Stage 5 (Ages >15): Adult hair distribution (medial thigh); adult genitalia/breast contour.

Clinical Pathology: Precocious and Delayed Puberty

  • Central Precocious Puberty (GnRH-Dependent):     * Due to excess GnRH (idiopathic or hypothalamic hamartoma) or pituitary tumors.     * Consonance is maintained. Treatment: GnRH analogues.
  • Peripheral Precocious Puberty (GnRH-Independent):     * Consonance is lost; FSHFSH/LHLH levels are low due to negative feedback.     * Testotoxicosis: Activating mutation of LH receptor; early androgen production without spermatogenesis (FSHFSH is low).     * McCune Albright Syndrome: Constitutive activation of adenylate cyclase; hyperactive signaling pathways.     * Leydig Cell Adenoma: High testosterone suppresses gonadotrophins.
  • Pubertal Delay:     * Defined as absence of secondary characteristics by age 1414 (boys) or 1313 (girls), or no menarche by age 1818.     * Constitutional Delay: Most common (9090 ᐱ); often hereditary or secondary to chronic illness (Diabetes, Cystic Fibrosis).     * Hypogonadotrophic Hypogonadism: Low FSHFSH/LHLH. Includes Kallman’s Syndrome (impaired migration of GnRH neurons; X-linked KAL gene).     * Hypergonadotrophic Hypogonadism: High FSHFSH/LHLH with non-responsive gonads (e.g., Klinefelter’s, Turner’s, Mumps).

Folliculogenesis and the Oocyte Life Cycle

  • Oogonia and Meiotic Arrest:     * Oogonia multiply by mitosis in the fetus.     * By 162416-24 weeks gestation, mitosis stops, and they enter meiosis I but arrest in Prophase I (Primary Oocytes).     * Arrest lasts until ovulation (1212 to 5252 years).
  • Follicle Structure:     * Primordial Follicle: Primary oocyte surrounded by a single layer of Granulosa cells and a basal lamina.     * Zona Pellucida (ZP): Acellular protective layer secreted by the oocyte; prevents polyspermy and facilitates nutrient transfer.     * Theca: Vascularized layer differentiating outside the basal lamina.
  • Stages of Growth:     1. Basal Growth: Gonadotrophin-independent; driven by local factors; takes 65+65+ days.     2. Antral Formation: Fluid-filled gaps (antrum) form. Antral follicles are visible on ultrasound.     3. Recruitment: Occurs during the intercycle rise in FSHFSH; takes 141514-15 days.     4. Dominant Follicle Selection: Only one follicle is selected for ovulation; others undergo atresia (degeneration).
  • 2-Cell-2-Gonadotrophin Theory:     * Theca Cells: Possess LHLH receptors; produce androgens.     * Granulosa Cells: Possess FSHFSH receptors; contain aromatase to convert internal and theca-derived androgens into estrogens.     * Note: Mid-follicular phase dominant follicles acquire LHLH receptors on Granulosa cells.
  • Atresia: The fate of most primordial follicles; the degeneration of those that do not ovulate.
  • Meiosis Completion:     * Meiosis I: Completed just before ovulation, producing a secondary oocyte and a polar body.     * Meiosis II: Arrests in Metaphase II; only completed if fertilization occurs.

The Menstrual Cycle and Uterine Changes

  • Endometrium Phases:     * Proliferative Phase: Driven by Estrogen; growth of the lining.     * Secretory Phase: Driven by Progesterone; differentiation of the lining.     * Menstruation: Triggered by the death of the Corpus Luteum and the subsequent fall in progesterone.
  • Myometrium: Muscular layer responsive to estrogen throughout life phases.
  • Cervical Mucus:     * High Estrogen (Mid-cycle): Low viscosity, edema, increased vascular permeability; permeable to sperm.     * High Progesterone (Luteal phase): Reduced fluid, high viscosity; inhospitable to sperm.
  • Uterine Tube:     * Estrogen: Favors epithelial differentiation of ciliated and secretory cells; promotes fertilization.     * Progesterone: Causes epithelial regression; environment becomes hostile to fertilization.
  • Tubal Patency Testing:     * Laparoscopy & Dye: Invasive visual check.     * HyCoSy: Non-invasive ultrasound with opaque medium.

Spermatogenesis and Male Reproductive Function

  • Seminiferous Tubules:     * Spermatogonia: Diploid germ cells undergoing mitosis.     * Primary Spermatocytes: Commit to meiosis; move to the adluminal compartment.     * Secondary Spermatocytes: Complete Meiosis I (23X+23Y23X + 23Y haploid sister chromatids).     * Spermatids: Result of Meiosis II (4 haploid cells).
  • Cell Regulation:     * Sertoli Cells: Maintain the population; possess FSHFSH receptors; form tight junctions (blood-testis barrier); secrete Androgen Binding Protein (ABPABP).     * Leydig Cells: Outside tubules; possess LHLH receptors; produce androgens.
  • Male Sexual Response:     * Erection: Parasympathetic; vasodilation of arteries to corpus cavernosum.     * Emission: Sympathetic.     * Ejaculation: Mainly sympathetic, with some somatic nerve involvement.
  • Glandular Secretions:     * Bulbo-urethral Gland: Pre-ejaculate; high salt, high pH to lubricate/neutralize the urethra.     * Seminal Vesicles: 507050-70 ᐱ of fluid; contains enzymes, fructose, high pH.     * Prostate: 3030 ᐱ of fluid; liquefaction enzymes, high zinc, antibacterial properties.

Fertilization, Implantation, and Embryo Development

  • Location: Fertilization occurs in the ampulla of the uterine tube.
  • Fertilization Steps:     1. Capacitation: Takes 4184-18 hours.     2. Sperm Penetration: Hyperactivated sperm penetrate the cumulus and bind to the Zona Pellucida (ZPZP).     3. Acrosome Reaction: Sperm enzymes cut through the ZPZP; sperm fuses with the plasma membrane.     4. Egg Activation: Phospholipase Z causes Ca2+Ca^{2+} release.     5. Cortical Reaction: Wave of Ca2+Ca^{2+} triggers release of proteases/peroxides to prevent polyspermy.     6. Syngamy: Completion of Meiosis II; expulsion of the second polar body; male and female pronuclei form, duplicate chromosomes, and align for mitosis.
  • Development Timeline:     * Day 3: Embryo has approximately 88 cells.     * Day 5: Blastocyst has approximately 100100 cells (comprised of Trophoblast, Blastocele, and Inner Cell Mass).     * Day 7: Implantation occurs.
  • hCG: Maintains the corpus luteum (CL) during early pregnancy until the placenta takes over (around week 7-8).

Physiological Changes During Pregnancy

  • Metabolic and Physical Changes:     * Weight Gain: 2 kg2\text{ kg} in the first 2020 weeks, followed by 0.5 kg/week0.5\text{ kg/week}; total gain of 913 kg9-13\text{ kg}.     * RAAS: Estrogen upregulates angiotensinogen; progesterone decreases vasoconstriction sensitivity; osmostat resets (decreased thirst threshold).     * GI System: Reduced motility (constipation), relaxed esophageal sphincter (acid reflux).
  • Circulation:     * Apparent Anemia: Plasma volume increases more than red cell mass.     * Cardiac Output: Increased stroke volume and cardiac output; peripheral vasodilation (via NONO) decreases total peripheral resistance (TPRTPR). Blood pressure typically decreases in the 1st1^{st} and 2nd2^{nd} trimesters.
  • Glucose Metabolism:     * 1st1^{st} Trimester: Increased insulin for glucose storage.     * 2nd2^{nd} Trimester: Placental lactogen causes insulin resistance to increase the glucose gradient for the fetus.
  • Respiratory: Minute volume increases by 4040 ᐱ; increased sensitivity to CO2CO_2 leads to increased arterial pO2pO_2 and decreased pCO2pCO_2.
  • Renal: Relaxin (via NONO and VEGFVEGF) and Progesterone cause vasodilation and increased Renal Blood Flow (RBFRBF) and Glomerular Filtration Rate (GFRGFR).
  • Thyroid: Thyroid hormone production increases; hCGhCG can act on TSHTSH receptors, potentially leading to gestational thyrotoxicosis (low TSHTSH).
  • Placental Endocrinology:     * The placenta aromatizes DHEADHEA from the fetal HPA axis into Estradiol (E2E_2).     * This shifts the E2/PE_2/P (Estrogen/Progesterone) ratio, increasing prostaglandin availability for uterine contractions and cervical ripening.     * CRH: Secreted by the placenta; increases ACTHACTH and DHEADHEA in the fetus and lung development (via cortisol).
  • Lactation:     * Prolactin: Controls milk production; produced by pituitary, myometrium, and placenta.     * Oxytocin: Stimulates milk-ejection reflex; released from the posterior pituitary in response to suckling.

Meiosis and Germ Cell Development

  • Interphase (S-Phase): Chromosomes duplicate into tetrads/sister chromatids.
  • Meiosis I:     * Prophase I: Alignment of tetrads; Crossing over (exchange of genetic material) occurs.     * Anaphase I: Sister chromatids move to opposite poles.     * Result: Two cells with unique sister chromatids (not identical due to crossing over).
  • Meiosis II:     * Metaphase II: Chromosomes align at the plate.     * Anaphase II: Sister chromatids separate.     * Result: Four unique haploid daughter cells.
  • Menopause: Defined by the depletion of primordial follicles, leading to the cessation of the menstrual cycle.